ALIVUS
LIFE SCIENCES
Evolve every day

April 03, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.,
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001

Ref: Scrip Code: 543322

To,
The Manager – Listing,
National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: ALIVUS

Dear Sirs,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We refer to our earlier letter dated 31st January, 2025 on the inspection conducted by USFDA for our API Manufacturing facility at Plot No. 3102 to 3109, 3103, GIDC Industrial Estate, Ankleshwar, Gujarat from 27th January, 2025 to 31st January, 2025. In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report ("EIR") with a Voluntary Action Indicated ("VAI") status for the said manufacturing facility.

Please take the information on your records.

Thanking You,

Your Sincerely,
For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA
Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2025.04.03 19:21:06 +05'30'

Rudalf Corriea
Company Secretary & Compliance officer